Frazier Healthcare’s newest venture partner is approaching her new gig with the smarts of a scientist, the gusto of an entrepreneur and the wisdom of a CEO who has both exited and shut down a company. Carol Gallagher joined the firm’s Menlo Park office this fall and told me it was a great opportunity to […]
A Seattle venture firm focusing its investments on biopharmaceutical companies is raising a new $400 million fund, according to U.S. Securities and Exchange Commission filings made last week. Frazier Healthcare’s seventh fund follows a $600 million fund formed in 2008. The firm’s investment strategy focuses on companies with development-stage biopharmaceutical therapeutics and occasionally medical devices. […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Antiviral therapies pharmaceutical company Chimerix has raised $45 million that it will apply toward further clinical development of two compounds, one of which could be used as a defense against biological attacks. The Durham, North Carolina-based company is developing another compound for infections associated with HIV.
OrbiMed Advisors, which has invested in Ohio companies Athersys Inc. and ViewRay, has raised $550 million for its latest health venture capital fund.